Estrogen Therapy, Re-Examined: What the Latest Research Actually Says

For the better part of two decades, one study did more to shape how women experienced menopause than almost anything else — and most of us have never actually read it. The Women’s Health Initiative, released back in 2002, found links between hormone therapy and increased risks of breast cancer, heart disease and stroke. The headlines were terrifying, prescriptions were pulled overnight, and an entire generation of women were left to white-knuckle their way through hot flushes, sleepless nights and brain fog with nothing but a shrug from their doctor.

Here’s what didn’t make the headlines: the study mostly involved women in their sixties, many of whom already had cardiovascular risk factors, using an oral form of hormone therapy that’s rarely prescribed today. The risks it found were real — but real for a specific group of women, using a specific formulation, at a specific and fairly late stage of life. Somewhere between the lab and the evening news, that nuance disappeared entirely, and “hormone therapy is dangerous” became the message every woman absorbed instead.

Twenty-plus years on, the correction is finally catching up. And it’s worth understanding what’s actually changed.

The FDA Just Overhauled Its Warning — And Australian Experts Are On Board

 Timing Turns Out to Matter Enormously

One of the clearest findings to emerge from the years of re-analysis is what’s often called the “timing hypothesis.” Starting hormone therapy within about ten years of menopause, or before the age of 60, is consistently linked to real cardiovascular benefit, because estrogen has a protective effect on blood vessels that’s strongest when it’s replaced close to when your body would naturally still be producing it. Wait too long past that window, and the same therapy doesn’t offer the same protection — which is part of why the original study, using women who were on average a decade past menopause, painted such a different picture.

Newer large-scale data is also pointing to benefits in women who start therapy during perimenopause itself, before periods have even stopped, rather than waiting until symptoms are severe.

What It Actually Protects, Not Just Treats

We tend to talk about hormone therapy purely as symptom relief — something for hot flushes and night sweats. That undersells it considerably.

Bone density. The years immediately around menopause are when bone loss accelerates fastest, with some women losing meaningful bone density in the first five to seven years alone. Starting hormone therapy in that window is one of the most well-evidenced ways to protect against fractures later in life, and fractures in older age carry real, serious consequences.

Metabolic health. Estrogen plays a genuine role in how your body regulates fat distribution, energy use and blood sugar. As it declines, women often notice weight settling differently, particularly around the midsection, even without any real change to diet or exercise. This isn’t a willpower failure — it’s a hormonal shift with a measurable physiological cause.

Cognitive symptoms. Current research increasingly supports what so many women have described anecdotally for years: hormone therapy can meaningfully ease brain fog and mood symptoms tied to the menopause transition, on top of its more well-known effects on hot flushes and vaginal dryness.

Prescriptions Are Rising Fast — For Good Reason

The shift in the research is translating into real change. Estrogen-based hormone therapy prescribing among women aged 45 to 54 has climbed sharply since 2018, with the increase accelerating notably since the FDA’s expert panel review. It’s a sign that both doctors and patients are catching up to where the evidence already was.

What Hasn’t Changed

None of this means hormone therapy is right for everyone, and the nuance matters here just as much as it did in 2002. Current medical guidance still recommends it primarily for symptomatic women under 60 or within ten years of menopause, and it isn’t advised for those with a history of breast cancer, active clotting disorders, or uncontrolled cardiovascular disease. It’s also worth noting that hormone therapy isn’t currently recommended as a stand-alone strategy purely for cardiovascular prevention — the benefit shows up as part of the broader picture, not as its main use case.

The form matters too. Transdermal estrogen — patches, gels and sprays — tends to carry a more favourable safety profile than the oral formulation used in the original 2002 study, particularly around clotting risk. This is a conversation worth having directly with a doctor who’s current on the research, not a decision to make from a headline, old or new.

The Bigger Picture

What strikes me most about this whole saga isn’t just the science — it’s how long it took to correct a message that shaped so many women’s lives. An entire generation was told to just push through, and plenty of women internalised that as their own failure to cope rather than the direct result of misapplied research.

If you’re approaching perimenopause or menopause and hormone therapy hasn’t come up in conversation with your doctor, it’s worth raising it yourself. The evidence has moved. It might be time your care did too.

*This article is general information, not personalised medical advice. Please speak with your doctor or a menopause specialist about what’s right for you.*